Skip to main content
. 2022 Oct 14;101(41):e30970. doi: 10.1097/MD.0000000000030970

Table 2.

Correlation between miR-92a and clinical characteristics of patients with non-small cell lung cancer. According to the expression level of miR-92a in tumor tissues. We divided 100 patients with non-small cell lung cancer into miR-92a high expression group (n = 50) and miR-92a low expression group (n = 50). The clinicopathological parameters of 100 patients with non-small cell lung cancer were measured. The clinicopathological parameters was expressed as a percentage.

Clinicopathological parameters N Expression of miR-92a χ2 P
High expression (n = 50) Low expression (n = 50)
Age (yr)
 <60 34 16 (32%) 18 (36%) 0.000 1.000
 ≥60 66 34 (68%) 32 (64%)
Gender
 Male 54 28 (56%) 26 (52%) 0.482 .628
 Female 46 22 (44%) 24 (48%)
Local invasion
 T1/T2 49 12 (24%) 37 (74%) 5.182 .039
 T3/T4 51 38 (76%) 13 (26%)
Organization type
 Squamous cell carcinoma 47 23 (46%) 24 (48%) 0.237 .769
 Adenocarcinoma 53 27 (54%) 26 (52%)
Tumor size
 ≥3 cm 51 26 (52%) 25 (50%) 0.254 .712
 <3 cm 49 24 (48%) 25 (50%)
Lymph node metastasis
 No 51 16 (32%) 35 (70%) 4.892 .042
 Yes 49 34 (68%) 15 (30%)
Distant metastasis
 M0 39 21 (42%) 31 (62%) 2.2815 .084
 M1 71 29 (58%) 19 (38%)
Clinical staging
 Stage I/II 32 13 (26%) 32 (64%) 6.748 .028
 Stage III/IV 68 37 (74%) 18 (36%)